Increased age has a negative impact on human cancer survival and directly correlates with increased incidence, malignancy and treatment resistance. However, little is known about the age-related mechanisms that impact cancer malignancy. Recent findings indicate that cancer can originate from early progenitors/ stem cells where oncogene can impose a specific tumoral fate. 1 Which role does age play here? There are many evidences indicating that aging has a clear impact both in the numbers and in the functionality of stem cells. [2] [3] [4] Therefore, any impact that age might have on the target cell-of-origin population may reflect in the characteristics of the cancer disease.
Investigating how age affects cancer development is crucial for understanding the process of disease development and to design prophylactic therapies. A major obstacle to elucidate the in vivo contribution of age to the development and evolution of cancer is the lack of appropriate mouse models where precise control of the timing of oncogene expression is possible. Recent studies of our group have taken advantage of a conditional transgenic mouse model of BCR-ABLp190-driven B-cell acute lymphoblastic leukemia (B-ALL) to evaluate the impact of agerelated mechanisms in B-ALL malignancy. 5 First, in order to clarify the direct impact of the age of the surrounding noncancerous cells on the survival of BCR-ABL + leukemic cells, the same number of B-ALL cells were injected intravenously into syngenic host mice of 4 or 20 mo of age. We found that there were no differences in survival between young and old recipient mice, therefore suggesting that the host age (that is, the age of the non-leukemic cellular environment) does not influence BCR-ABL + B-ALL malignancy. There is a great lack of knowledge about the relationship between the age of the target cell and the genesis of cancer. Therefore, we further examined how the age of target cell impacts on the BCR-ABL oncogene-mediated reprogramming.
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Immortal but vulnerable
To that end, we have taken advantage of the doxycline-controlled transgenic CombitTA-BCR-ABLp190 mouse line, to induce the expression of the leukemiatriggering oncogene in mice of different ages. We found that the malignancy of the induced B-ALL increases with the age of the normal progenitors from which the disease arises. Leukaemias originating from older progenitors present a more aggressive phenotype, and have a much faster evolution than leukemias initiating from young progenitors. Our results also imply that, to a great extent, disease evolution is programmed from the beginning, since the starting cell determines the aggressiveness of the phenotype; also, our data indicate that the decline of the immune response with age is not responsible for the increased development or aggressiveness of the tumors in the elderly, although these findings do not exclude that the number of the appropriate target cells available for transformation should be taken into account. 6 Nevertheless, this finding is consistent with the previous observation indicating that the host age does not influence BCR-ABL + ALLs malignancy. Altogether, these findings provide the first in vivo experimental evidence, using a conditional transgenic mouse model, showing that an increase in the age at which transformation occurs has a direct impact in the malignant potential of cancer cells. This is in agreement with clinical observations showing that age-related cell intrinsic factors may play a leading role in the impact of age on B-ALL malignancy. 7 Independently of our work, Henry et al. began their studies by looking at the effect of BCR-ABL in aging-associated leukemogenesis by using a retroviral transduction system. 8 They found that aged B-cell progenitors present a reduced fitness due to impaired signaling machinery and that, since the oncogene compensates in part the need for kinase signaling, its expression promotes the positive selection of BCR-ABL + cells. 8 In spite of the opposite starting points of these two studies, both of them come to a remarkably consistent conclusion: the age of the target cell influences leukemogenesis. On the other hand, while Henry et al. showed that both cellintrinsic and extrinsic factors influence the biology of the BCR-ABL + malignancy, we found that the main drivers of the BCR-ABL + malignancies are qualitative and/or quantitative characteristics of the target cells. Moreover, the key aspect of our experimental approach is that BCR-ABL is not activated until after transplantation and, therefore, conveniently bypasses doubts over required exposures for the natural disease and age-associated alterations in the host tissue microenvironment (Fig. 1) . The major questions that arise in light of these findings are how oncogene reprogramming impacts on the age of target cell, 9, 10 and what are the qualitative and/or quantitative figures that make aged stem/progenitor target cells more vulnerable to malignancy. Mouse models of cancer where precise control of the timing of the oncogene exposure is possible will be instrumental to address these and other questions to understand the complexity of ageassociated cancers. 
